01 June 2018
Home grown success story drives the commercialisation of Colvera™, a liquid biopsy test for colorectal cancer (CRC) recurrence, and the focus of growing clinical evidence to support its use as the first widely adopted blood test for screening for colorectal cancer.
OneVentures played a key role in the financing by increasing their position in Clinical Genomics and enabling many of their limited partners to invest further.
OneVentures Managing Partner and Clinical Genomics Director Paul Kelly MD said, “The company is poised to achieve some very significant milestones over the next couple years that should further drive revenue and value growth.”
Posted in — The Australian